Published in Oncology (Williston Park) on March 01, 2011
AR function in promoting metastatic prostate cancer. Cancer Metastasis Rev (2014) 0.91
Putting Provenge in perspective. Oncology (Williston Park) (2011) 0.75
The unfolding treatment landscape for men with castration-resistant prostate cancer. Clin Investig (Lond) (2011) 0.75
Prostate cancer immunotherapy: the role for sipuleucel-T and other immunologic approaches. Oncology (Williston Park) (2011) 0.75
Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med (2010) 29.75
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol (2008) 18.54
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med (2015) 8.80
Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res (2009) 5.10
Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst (2007) 5.10
Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators. J Clin Oncol (2007) 3.05
Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res (2008) 2.84
Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma. J Urol (2008) 2.03
Lack of pathologic down-staging with neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma of the bladder: a contemporary series. Cancer (2009) 2.02
Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy. J Clin Oncol (2011) 1.92
Chronic kidney disease after nephroureterectomy for upper tract urothelial carcinoma and implications for the administration of perioperative chemotherapy. Cancer (2010) 1.77
Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study. J Urol (2007) 1.75
ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings. Eur Urol (2012) 1.66
Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy. J Urol (2007) 1.66
The effect of sunitinib on primary renal cell carcinoma and facilitation of subsequent surgery. J Urol (2012) 1.65
The investigational Aurora kinase A inhibitor MLN8237 induces defects in cell viability and cell-cycle progression in malignant bladder cancer cells in vitro and in vivo. Clin Cancer Res (2013) 1.62
Phase II clinical trial design: methods in translational research from the Genitourinary Committee at the Eastern Cooperative Oncology Group. Clin Cancer Res (2006) 1.60
Risk for developing myelodysplastic syndromes in prostate cancer patients definitively treated with radiation. J Natl Cancer Inst (2014) 1.56
Appetite and cancer-associated anorexia: a review. J Clin Oncol (2004) 1.56
A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. Lancet Oncol (2011) 1.33
A phase I dose-escalation study of Tivantinib (ARQ 197) in adult patients with metastatic solid tumors. Clin Cancer Res (2011) 1.27
Squamous cell carcinoma of the bladder: a clinicopathologic analysis of 45 cases. Am J Surg Pathol (2007) 1.26
Toxicity of sunitinib plus bevacizumab in renal cell carcinoma. J Clin Oncol (2010) 1.23
Metastasectomy after targeted therapy in patients with advanced renal cell carcinoma. J Urol (2010) 1.22
A phase I study of sunitinib plus bevacizumab in advanced solid tumors. Clin Cancer Res (2009) 1.19
Systemic chemotherapy for advanced bladder cancer: update and controversies. J Clin Oncol (2006) 1.18
Neoadjuvant docetaxel treatment for locally advanced prostate cancer: a clinicopathologic study. Cancer (2007) 1.09
Management of side effects associated with sunitinib therapy for patients with renal cell carcinoma. Onco Targets Ther (2009) 1.07
Brain metastases from bladder carcinoma: presentation, treatment and survival. J Urol (2002) 1.02
Phase II study of lenalidomide in patients with metastatic renal cell carcinoma. Cancer (2006) 1.02
Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab. Cancer (2010) 1.02
Phase II study of KOS-862 in patients with metastatic androgen independent prostate cancer previously treated with docetaxel. Invest New Drugs (2007) 1.01
Bladder cancer: narrowing the gap between evidence and practice. J Clin Oncol (2009) 1.01
HER2 overexpression and amplification in urothelial carcinoma of the bladder is associated with MYC coamplification in a subset of cases. Am J Clin Pathol (2008) 1.00
Phase II study on the addition of ASA404 (vadimezan; 5,6-dimethylxanthenone-4-acetic acid) to docetaxel in CRMPC. Clin Cancer Res (2010) 0.98
HER2 gene amplification occurs frequently in the micropapillary variant of urothelial carcinoma: analysis by dual-color in situ hybridization. Mod Pathol (2011) 0.98
Sunitinib-induced macrocytosis in patients with metastatic renal cell carcinoma. Cancer (2008) 0.97
A model that predicts the probability of positive imaging in prostate cancer cases with biochemical failure after initial definitive local therapy. J Urol (2008) 0.95
Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer. Support Care Cancer (2007) 0.95
Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma. Cancer (2013) 0.94
The impact of tumor burden characteristics in patients with metastatic renal cell carcinoma treated with sunitinib. Cancer (2010) 0.92
Phase I trial of pomalidomide given for patients with advanced solid tumors. Cancer Chemother Pharmacol (2012) 0.90
Clinical and biological effects of neoadjuvant sargramostim and thalidomide in patients with locally advanced prostate carcinoma. Clin Cancer Res (2008) 0.88
Cessation of vascular endothelial growth factor-targeted therapy in patients with metastatic renal cell carcinoma: feasibility and clinical outcome. Cancer (2011) 0.86
A phase 1, multicenter, open-label study of the safety of two dose levels of a human monoclonal antibody to human α(v) integrins, intetumumab, in combination with docetaxel and prednisone in patients with castrate-resistant metastatic prostate cancer. Invest New Drugs (2010) 0.86
The atypical urothelial cancer patient: management of bladder cancers of non-transitional cell histology and cancers of the ureters and renal pelvis. Semin Oncol (2007) 0.84
Phase I/II trial of 5-fluorouracil and a noncytotoxic dose level of suramin in patients with metastatic renal cell carcinoma. Clin Genitourin Cancer (2008) 0.83
Phase I/II trial of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer. Clin Prostate Cancer (2004) 0.83
Clinical and immunomodulatory effects of celecoxib plus interferon-alpha in metastatic renal cell carcinoma patients with COX-2 tumor immunostaining. J Clin Immunol (2011) 0.83
A phase I study of zibotentan (ZD4054) in patients with metastatic, castrate-resistant prostate cancer. Invest New Drugs (2009) 0.83
Phase I trial of consensus interferon in patients with metastatic renal cell carcinoma: toxicity and immunological effects. Clin Cancer Res (2003) 0.83
The future of drug development in urothelial cancer. J Clin Oncol (2011) 0.82
Phase II trial of capecitabine and rHu-interferon-alpha-2a in patients with metastatic renal cell carcinoma, limited efficacy, and moderate toxicity. Urol Oncol (2007) 0.81
Hormonal therapy for prostate cancer: primum non nocere. Urology (2002) 0.81
Gemcitabine and docetaxel in metastatic, castrate-resistant prostate cancer: results from a phase 2 trial. Cancer (2010) 0.81
Second-line chemotherapy for advanced urothelial cancer: because we should or because we can? J Clin Oncol (2009) 0.80
Paracolic recurrence of stage I seminoma. Urology (2003) 0.80
Piritrexim in advanced, refractory carcinoma of the urothelium (E3896): a phase II trial of the Eastern Cooperative Oncology Group. Invest New Drugs (2002) 0.80
Phase I/II trial of subcutaneous interleukin-2, granulocyte-macrophage colony-stimulating factor and interferon-α in patients with metastatic renal cell carcinoma. BJU Int (2011) 0.80
Adjuvant and neoadjuvant chemotherapy for bladder cancer: management and controversies. Nat Clin Pract Urol (2005) 0.80
Southwest Oncology Group phase II study of arsenic trioxide in patients with refractory germ cell malignancies. Cancer (2006) 0.79
Clinical and immunomodulatory effects of bevacizumab and low-dose interleukin-2 in patients with metastatic renal cell carcinoma: results from a phase II trial. BJU Int (2010) 0.79
Presentation, location and overall survival of pelvic recurrence after radical cystectomy for transitional cell carcinoma of the bladder. BJU Int (2007) 0.79
Society of Urologic Oncology position statement: redefining the management of hormone-refractory prostate carcinoma. Cancer (2005) 0.79
Randomized, double-blind, placebo-controlled phase II trial of maintenance sunitinib versus placebo after chemotherapy for patients with advanced urothelial carcinoma: scientific rationale and study design. Clin Genitourin Cancer (2007) 0.79
Advanced bladder cancer: so many drugs, so little progress : what's wrong with this picture? Cancer (2008) 0.78
Zibotentan for the treatment of castrate-resistant prostate cancer. Expert Opin Investig Drugs (2010) 0.78
Differential immunologic and microRNA effects of 2 dosing regimens of recombinant human granulocyte/macrophage colony stimulating factor. J Immunother (2012) 0.77
Phase I trial of PEG-interferon and recombinant IL-2 in patients with metastatic renal cell carcinoma. Cancer Chemother Pharmacol (2007) 0.77
A phase II study of 13-cis retinoic acid plus interferon alpha-2a in advanced stage penile carcinoma: an Eastern Cooperative Oncology Group study (E3893). Cancer Invest (2003) 0.77
Traditional approaches to androgen deprivation therapy. Urology (2011) 0.77
Indications and practice with androgen deprivation therapy. Urology (2011) 0.77
A phase II study of tandutinib (MLN518), a selective inhibitor of type III tyrosine receptor kinases, in patients with metastatic renal cell carcinoma. Invest New Drugs (2010) 0.76
Focusing on testosterone. Urology (2011) 0.76
Phase I trial of thalidomide and interleukin-2 in patients with metastatic renal cell carcinoma. Invest New Drugs (2006) 0.76
Revisiting truth and consequences: what to do when the patient doesn't want to know. J Clin Oncol (2002) 0.75
Initial experience with single-agent docetaxel as neoadjuvant therapy in men with locally advanced prostate cancer. Rev Urol (2003) 0.75
Systems pathology and predicting outcome after radical prostatectomy. J Clin Oncol (2008) 0.75
Initial experience with single-agent docetaxel as neoadjuvant therapy in men with locally advanced prostate cancer. Rev Urol (2003) 0.75
Maximizing outcomes in genitourinary cancers across the treatment continuum. BJU Int (2011) 0.75
Novel cytotoxic and biological agents for prostate cancer: where will the money be in 2005? Eur J Cancer (2005) 0.75
New data, new paradigms for treating patients with prostate cancer: introduction. Urology (2011) 0.75
Management of stage I nonseminomatous germ-cell tumors. Semin Urol Oncol (2002) 0.75